Compendium of aberrant DNA methylation and histone modifications in cancer

Biochemical and Biophysical Research Communications

Volumn 455, Issue 1-2, 2014, Pages 3-9

  Hattori, Naoko ^a   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Cancer; DNA methylation; Epigenetics; Histone modification

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 HYDROXYMETHYLCYTOSINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; GSK 126; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; PROTEIN MLH1; TEMOZOLOMIDE; TEN ELEVEN TRANSLOCATION PROTEIN; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; HISTONE;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER THERAPY; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE MUTATION; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTONE MODIFICATION; HUMAN; NEOPLASM; NONHUMAN; PHENOTYPE; REVIEW; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; GLIOMA; HISTORY; METABOLISM; MUTATION; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GLIOMA; HISTONES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; MUTATION; NEOPLASMS;

EID: 84912080765     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.08.140     Document Type: Review

References (106)

1. M. Saitou, S. Kagiwada, and K. Kurimoto Epigenetic reprogramming in mouse pre-implantation development and primordial germ cells Development 139 2012 15 31
2. W. Reik, W. Dean, and J. Walter Epigenetic reprogramming in mammalian development Science 293 2001 1089 1093
3. A. Meissner Epigenetic modifications in pluripotent and differentiated cells Nat. Biotechnol. 28 2010 1079 1088
4. M.K. Skinner Role of epigenetics in developmental biology and transgenerational inheritance Birth Defects Res. C Embryo Today 93 2011 51 55
5. D.D. De Carvalho, J.S. You, and P.A. Jones DNA methylation and cellular reprogramming Trends Cell Biol. 20 2010 609 617
6. K. Ohnishi, K. Semi, and Y. Yamada Epigenetic regulation leading to induced pluripotency drives cancer development in vivo Biochem. Biophys. Res. Commun. 2014 10.1016/j.bbrc.2014.07.020
7. T. Ushijima, N. Watanabe, and E. Okochi Fidelity of the methylation pattern and its variation in the genome Genome Res. 13 2003 868 874
8. T. Ushijima Detection and interpretation of altered methylation patterns in cancer cells Nat. Rev. Cancer 5 2005 223 231
9. A.P. Feinberg, and B. Vogelstein Hypomethylation distinguishes genes of some human cancers from their normal counterparts Nature 301 1983 89 92
10. N. Ohtani-Fujita, T. Fujita, and A. Aoike CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene Oncogene 8 1993 1063 1067
11. M. Toyota, N. Ahuja, and M. Ohe-Toyota CpG island methylator phenotype in colorectal cancer Proc. Natl. Acad. Sci. USA 96 1999 8681 8686
12. M. Abe, M. Ohira, and A. Kaneda CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas Cancer Res. 65 2005 828 834
13. Y. Hoshikawa, H.J. Kwon, and M. Yoshida Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines Exp. Cell Res. 214 1994 189 197
14. T. Jenuwein, and C.D. Allis Translating the histone code Science 293 2001 1074 1080
15. C. Plass, S.M. Pfister, and A.M. Lindroth Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer Nat. Rev. Genet. 14 2013 765 780
16. V.A. DeWoskin, and R.P. Million The epigenetics pipeline Nat. Rev. Drug Discov. 12 2013 661 662
17. M.A. Gama-Sosa, V.A. Slagel, and R.W. Trewyn The 5-methylcytosine content of DNA from human tumors Nucleic Acids Res. 11 1983 6883 6894
18. A.P. Feinberg, C.W. Gehrke, and K.C. Kuo Reduced genomic 5-methylcytosine content in human colonic neoplasia Cancer Res. 48 1988 1159 1161
19. S.E. Goelz, B. Vogelstein, and S.R. Hamilton Hypomethylation of DNA from benign and malignant human colon neoplasms Science 228 1985 187 190
20. Y. Matsuda, S. Yamashita, and Y.C. Lee Hypomethylation of Alu repetitive elements in esophageal mucosa, and its potential contribution to the epigenetic field for cancerization Cancer Causes Control 23 2012 865 873
21. T. Yoshida, S. Yamashita, and T. Takamura-Enya Alu and Satalpha hypomethylation in Helicobacter pylori-infected gastric mucosae Int. J. Cancer 128 2011 33 39
22. C. De Smet, O. De Backer, and I. Faraoni The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation Proc. Natl. Acad. Sci. USA 93 1996 7149 7153
23. B. Cho, H. Lee, and S. Jeong Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma Biochem. Biophys. Res. Commun. 307 2003 52 63
24. M. Cho, H. Uemura, and S.C. Kim Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma Br. J. Cancer 85 2001 563 567
25. Y. Akiyama, C. Maesawa, and S. Ogasawara Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells Am. J. Pathol. 163 2003 1911 1919
26. N. Sato, A. Maitra, and N. Fukushima Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma Cancer Res. 63 2003 4158 4166
27. M. Nishigaki, K. Aoyagi, and I. Danjoh Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays Cancer Res. 65 2005 2115 2124
28. R.Z. Chen, U. Pettersson, and C. Beard DNA hypomethylation leads to elevated mutation rates Nature 395 1998 89 93
29. F. Gaudet, J.G. Hodgson, and A. Eden Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
30. A. Merlo, J.G. Herman, and L. Mao 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers Nat. Med. 1 1995 686 692
31. M.F. Kane, M. Loda, and G.M. Gaida Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines Cancer Res. 57 1997 808 811
32. K. Yoshiura, Y. Kanai, and A. Ochiai Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas Proc Natl. Acad. Sci. USA 92 1995 7416 7419
33. J. Kawai, S. Hirotsune, and K. Hirose Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method Nucleic Acids Res. 21 1993 5604 5608
34. T. Ushijima, K. Morimura, and Y. Hosoya Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors Proc. Natl. Acad. Sci. USA 94 1997 2284 2289
35. M.L. Gonzalgo, G. Liang, and C.H. Spruck 3rd Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR Cancer Res. 57 1997 594 599
36. M. Sonnet, C. Baer, and M. Rehli Enrichment of methylated DNA by methyl-CpG immunoprecipitation Methods Mol. Biol. 971 2013 201 212
37. N. Touleimat, and J. Tost Complete pipeline for Infinium((R)) Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation Epigenomics 4 2012 325 341
38. A. Meissner, A. Gnirke, and G.W. Bell Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis Nucleic Acids Res. 33 2005 5868 5877
39. F. Miura, Y. Enomoto, and R. Dairiki Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging Nucleic Acids Res. 40 2012 e136
40. S. Yamashita, K. Hosoya, and K. Gyobu Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis DNA Res. 16 2009 275 286
41. M. Toyota, C. Ho, and N. Ahuja Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification Cancer Res. 59 1999 2307 2312
42. H. Noushmehr, D.J. Weisenberger, and K. Diefes Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522
43. S.C. Mack, H. Witt, and R.M. Piro Epigenomic alterations define lethal CIMP-positive ependymomas of infancy Nature 506 2014 445 450
44. M. Toyota, N. Ahuja, and H. Suzuki Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype Cancer Res. 59 1999 5438 5442
45. C. An, I.S. Choi, and J.C. Yao Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma Clin. Cancer Res. 11 2005 656 663
46. Y. Toiyama, Y. Okugawa, and A. Goel DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer Biochem. Biophys. Res. Commun. 455 2014 43 57
47. J. Tanaka, T. Watanabe, and T. Kanazawa Left-Sided microsatellite unstable colorectal cancers show less frequent methylation of hMLH1 and CpG island methylator phenotype than right-sided ones J. Surg. Oncol. 96 2007 611 618
48. K. Asada, M. Abe, and T. Ushijima Clinical application of the CpG island methylator phenotype to prognostic diagnosis in neuroblastomas J. Hum. Genet. 58 2013 428 433
49. H. Suzuki, E. Yamamoto, and R. Maruyama Biological significance of the CpG island methylator phenotype Biochem. Biophys. Res. Commun. 2014 10.1016/j.bbrc.2014.07.007
50. S. Turcan, D. Rohle, and A. Goenka IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483 2012 479 483
51. J.K. Killian, S.Y. Kim, and M. Miettinen Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor Cancer Discov. 3 2013 648 657
52. S.C. Wu, and Y. Zhang Active DNA demethylation: many roads lead to Rome Nat. Rev. Mol. Cell Biol. 11 2010 607 620
53. M. Tahiliani, K.P. Koh, and Y. Shen Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 Science 324 2009 930 935
54. J.J. Waterfall, J.K. Killian, and P.S. Meltzer The role of mutation of metabolism-related genes in genomic hypermethylation Biochem. Biophys. Res. Commun. 2014 10.1016/j.bbrc.2014.08.003
55. S. Ito, L. Shen, and Q. Dai Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine Science 333 2011 1300 1303
56. M. Ko, Y. Huang, and A.M. Jankowska Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 Nature 468 2010 839 843
57. C.G. Lian, Y. Xu, and C. Ceol Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma Cell 150 2012 1135 1146
58. C.H. Hsu, K.L. Peng, and M.L. Kang TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases Cell Rep. 2 2012 568 579
59. M.F. Fraga, E. Ballestar, and A. Villar-Garea Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer Nat. Genet. 37 2005 391 400
60. J. Ellinger, P. Kahl, and J. von der Gathen Global levels of histone modifications predict prostate cancer recurrence Prostate 70 2010 61 69
61. A. Manuyakorn, R. Paulus, and J. Farrell Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704 J. Clin. Oncol. 28 2010 1358 1365
62. Y. Kondo, L. Shen, and A.S. Cheng Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation Nat. Genet. 40 2008 741 750
63. S.Y. Jo, E.M. Granowicz, and I. Maillard Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation Blood 117 2011 4759 4768
64. M.W. Chen, K.T. Hua, and H.J. Kao H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM Cancer Res. 70 2010 7830 7840
65. K. Horiuchi, D. Fujimoto, and M. Fukushima Increased histone acetylation and deacetylation in rat ascites hepatoma cells Cancer Res. 41 1981 1488 1491
66. M. Yoshida, S. Nomura, and T. Beppu Effects of trichostatins on differentiation of murine erythroleukemia cells Cancer Res. 47 1987 3688 3691
67. S. Aumann, and O. Abdel-Wahab Somatic alterations and dysregulation of epigenetic modifiers in cancers Biochem. Biophys. Res. Commun. 2014 10.1016/j.bbrc.2014.08.004
68. A. Tefferi, R.L. Levine, and K.H. Lim Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates Leukemia 23 2009 900 904
69. O. Abdel-Wahab, A. Mullally, and C. Hedvat Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Blood 114 2009 144 147
70. K.E. Yen, M.A. Bittinger, and S.M. Su Cancer-associated IDH mutations: biomarker and therapeutic opportunities Oncogene 29 2010 6409 6417
71. L. Dang, D.W. White, and S. Gross Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
72. W. Xu, H. Yang, and Y. Liu Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases Cancer Cell 19 2011 17 30
73. X.J. Yan, J. Xu, and Z.H. Gu Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia Nat. Genet. 43 2011 309 315
74. D.A. Russler-Germain, D.H. Spencer, and M.A. Young The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers Cancer Cell 25 2014 442 454
75. C.J. Sneeringer, M.P. Scott, and K.W. Kuntz Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas Proc. Natl. Acad. Sci. USA 107 2010 20980 20985
76. G. Nikoloski, S.M. Langemeijer, and R.P. Kuiper Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes Nat. Genet. 42 2010 665 667
77. R.D. Morin, N.A. Johnson, and T.M. Severson Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat. Genet. 42 2010 181 185
78. G.L. Dalgliesh, K. Furge, and C. Greenman Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes Nature 463 2010 360 363
79. G. van Haaften, G.L. Dalgliesh, and H. Davies Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer Nat. Genet. 41 2009 521 523
80. J. Schwartzentruber, A. Korshunov, and X.Y. Liu Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma Nature 482 2012 226 231
81. D. Sturm, H. Witt, and V. Hovestadt Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma Cancer Cell 22 2012 425 437
82. T. Ushijima, and K. Asada Aberrant DNA methylation in contrast with mutations Cancer Sci. 101 2010 300 305
83. D. Dhanak, and P. Jackson Development and classes of epigenetic drugs for cancer Biochem. Biophys. Res. Commun. 2014 10.1016/j.bbrc.2014.07.006
84. F. Sorm, A. Piskala, and A. Cihak 5-Azacytidine, a new, highly effective cancerostatic Experientia 20 1964 202 203
85. F. Sorm, and J. Vesely Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice Neoplasma 15 1968 339 343
86. S.M. Taylor, and P.A. Jones Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine Cell 17 1979 771 779
87. G.E. Rivard, R.L. Momparler, and J. Demers Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia Leuk. Res. 5 1981 453 462
88. J.P. Issa, G. Garcia-Manero, and F.J. Giles Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
89. L.R. Silverman, E.P. Demakos, and B.L. Peterson Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J. Clin. Oncol. 20 2002 2429 2440
90. H. Kantarjian, J.P. Issa, and C.S. Rosenfeld Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 2006 1794 1803
91. R.A. Juergens, J. Wrangle, and F.P. Vendetti Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer Cancer Discov. 1 2011 598 607
92. N. Azad, C.A. Zahnow, and C.M. Rudin The future of epigenetic therapy in solid tumours-lessons from the past Nat. Rev. Clin. Oncol. 10 2013 256 266
93. R.L. Piekarz, R. Robey, and V. Sandor Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report Blood 98 2001 2865 2868
94. A.A. Lane, and B.A. Chabner Histone deacetylase inhibitors in cancer therapy J. Clin. Oncol. 27 2009 5459 5468
95. S. Kubicek, R.J. O'Sullivan, and E.M. August Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase Mol. Cell 25 2007 473 481
96. H.S. Cho, J.D. Kelly, and S. Hayami Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1 Neoplasia 13 2011 676 684
97. M.T. McCabe, H.M. Ott, and G. Ganji EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 492 2012 108 112
98. S.K. Knutson, N.M. Warholic, and T.J. Wigle Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proc. Natl. Acad. Sci. USA 110 2013 7922 7927
99. J. Loven, H.A. Hoke, and C.Y. Lin Selective inhibition of tumor oncogenes by disruption of super-enhancers Cell 153 2013 320 334
100. T.M. Barrow, and K.B. Michels Epigenetic epidemiology of cancer Biochem. Biophys. Res. Commun. 2014 10.1016/j.bbrc.2014.08.002
101. T. Ushijima Epigenetic field for cancerization J. Biochem. Mol. Biol. 40 2007 142 150
102. K. Asada, T. Nakajima, and T. Shimazu Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study Gut 2014 Published Online First: 2 June 2014
103. J.D. Warren, W. Xiong, and A.M. Bunker Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer BMC Med. 9 2011 133
104. L. Van Neste, J.G. Herman, and G. Otto The epigenetic promise for prostate cancer diagnosis Prostate 72 2012 1248 1261
105. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N. Engl. J. Med. 352 2005 997 1003
106. R. Jover, T.P. Nguyen, and L. Perez-Carbonell 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer Gastroenterology 140 2011 1174 1181